Soft Tissue Regeneration, Inc. (“STR”) has developed and preliminarily tested a potential breakthrough technology for soft tissue regeneration of the anterior cruciate ligament (“ACL”) of the knee. This patented and proprietary technology, using an FDA-approved polymer called polyL-lactide (PLLA), already widely used in biomedical devices, could allow STR to address a tremendous unmet need in the repair of musculoskeletal soft tissue injuries of the knee. The product is called the L-C Ligament™ for ACL reconstruction. It is a synthetic scaffold that stabilizes the knee and encourages the regeneration of ligament tissue and should result in faster, better healing and greater odds of making a full recovery. STR was founded based on technologies developed by Cato T. Laurencin, M.D., Ph.D.